Most recent update: Monday, July 15, 2019 - 08:50

Bariatric News - Cookies & privacy policy

You are here

Adropin hormone

Study finds adropin hormone can improve insulin action

Low levels of the hormone observed in obesity may contribute to diabetes and the reduced ability of the body to use glucose

Researchers from Saint Louis University have found that adropin, a hormone that regulates whether the body burns fat or sugar during feeding and fasting cycles, can improve insulin action in obese, diabetic mice, suggesting that it may work as a therapy for type 2 diabetes. The study 'Therapeutic effects of adropin on glucose tolerance and substrate utilization in diet-induced obese mice with insulin resistance', was published in Molecular Metabolism.

"Adropin is a poorly understood hormone," said Dr Andrew Butler, professor of pharmacological and physiological science at Saint Louis University. "We first reported its discovery a little over six years ago, but we really didn't understand what it did. We knew it played a role in maintaining metabolic health, but we didn't know much beyond that."

"When we measured adropin levels in mice, they were suppressed under fasting conditions and stimulated after feeding, suggesting functions related to the changes in metabolism that occur with feeding and fasting," he said. "Our work suggests that adropin plays a role in regulating metabolic (energy) homeostasis.

Andrew Butler

The paper reports that low levels of the hormone observed in obesity may contribute to diabetes and the reduced ability of the body to use glucose, and reports that treatment with adropin improved glucose tolerance, enhanced insulin action and improved metabolic flexibility toward glucose utilisation in situations of obesity and insulin resistance.

"Basically, when you are well fed, your body prefers to use glucose and the release of adropin supports this change by enhancing the use of glucose as a metabolic fuel in muscle,” he explained. “However, when you are fasting, your body prefers to use fatty acids. Our observations suggest that a decline in adropin with fasting may be a signal to "take the brakes off" the use of fatty acids."

“The hope is that adropin could someday be used in the clinic to help patients with type 2 diabetes control blood sugar levels and delay or prevent the development of the disease in at-risk individuals." 

To access this article, please click here

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.